FOLH1 and prostate cancer: Although [18F]AlF-PSMA-137 PET/CT imaging did not change the stage of these prostate cancer patients, it showed low blood uptake and higher tumor-to-organ ratios at delayed time (Figure 7), which could improve the imaging contrast.